Fig. 2
From: Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics
Flow chart showing the distribution of study subjects and medications used for KD in the conventional group. The numbers in parentheses denote the overall number of patients in the conventional group, and the number of patients in the conventional group whose risk scores were ≥5 points, respectively. IVIG: intravenous immunoglobulin, IFX: infliximab, CyA: cyclosporin, mPSL: methylprednisolone